Upcoming Workshops
For Breast Cancer
For Mantle Cell Lymphoma
Past workshops
For All Cancers
- Clinical Trials: How They Transform the Treatment of Cancer
- Clinical Trials: How They Transform the Treatment of Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Clinical Trials: How They Transform the Treatment of Cancer
- Update on Clinical Trials: How They Work
- Trends in Oncology and Treatment Planning: What You Need to KnowPart I of Life with Cancer: A Guide to Getting the Best Care
For Acute Lymphoblastic Leukemia
For Acute Myeloid Leukemia
For Basal Cell Cancer
For Bladder Cancer
For Bone Cancer
For Brain Cancer
For Breast Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part I of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
For Chronic Lymphocytic Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Chronic Myelogenous Leukemia
For Colorectal Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Advances in the Treatment of Colorectal Cancer
- Colorectal Cancer Treatment: Progress and Advances
- Colorectal Cancer Treatment: Progress & Advances
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Cutaneous T-Cell Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Diffuse Large B-Cell Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Diffuse Large B-Cell Lymphoma (DLBCL) Updates
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Follicular Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Head and Neck Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part I of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Oral, Head and Neck Cancer: Treatment Updates
- Oral, Head & Neck Cancer: Treatment Update
For Hodgkin Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Liver Cancer
For Lung Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Update on Small Cell Lung CancerPart I of Living with Small Cell Lung Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Non-Small Cell Lung Cancer: Biomarker Testing & Treatment TrendsPart II of Living with Non-Small Cell Lung Cancer
- What’s New in Diagnostic Technologies for People Living with Small Cell Lung CancerPart II of Living with Small Cell Lung Cancer
- Genomic Testing and Current Trends in the Treatment of Non-Small Cell Lung CancerPart III of Living with Non-Small Cell Lung Cancer
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Diffuse Large B-Cell Lymphoma (DLBCL) Updates
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Mantle Cell Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Marginal Zone Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Melanoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Mesothelioma
For Metastatic Breast Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
For Multiple Myeloma
- Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Multiple Myeloma
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Multiple Myeloma
For Myelodysplastic Syndromes
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Myeloproliferative Neoplasms
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Non-Hodgkin Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Ovarian Cancer
For Pancreatic Cancer
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
For Peripheral T-Cell Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Prostate Cancer
For Sarcoma
For Skin Cancer
For Small Lymphocytic Lymphoma
- Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
For Squamous Cell Cancer
For Triple Negative Breast Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
- The Benefits of Clinical Trials for Triple Negative Breast Cancer